The collaboration highlights the rising importance of intranasal delivery in developing non-vaccine approaches to respiratory disease prevention
The funding comes under the AHG Catalysing Innovation Awards, part of the Addiction Healthcare Goals programme led by the Office for Life Sciences
The recommendation covers FYLREVY 14.2 mg and 18.9 mg for non-hysterectomised postmenopausal women experiencing oestrogen deficiency symptoms at least 12 months after their last menses
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant
The low-profile, 2” Disc Top Lite closure offers lighter weight combined with premium customization options
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
PICCOLO trial met its primary endpoint of objective response rate (ORR)
Subscribe To Our Newsletter & Stay Updated
